Volume 160, Issue 6 p. 1362
Free Access

Erratum

In the article by Hoeger et al.1 an error was published in Table 1. The days studied for the vehicle group should read 1138, and not 11 380 as was published.

Table 1. Crude rates and corresponding incidence density of the most common (≥ 2%) treatment-emergent adverse events in the double-blind phase
Pimecrolimus cream 1% Vehicle
Crude rates (N =99), n (%) Incidence density (days studied = 1568), n = events (ID) Crude rates (N =101), n (%) Incidence density (days studied = 1138), n = events (ID)
Any primary system organ class 40 (40·4) 76 (48·5) 34 (33·7) 60 (52·7)
Nasopharyngitis 13 (13·1) 13 (8·3) 12 (11·9) 14 (12·3)
Application site irritation 5 (5·1) 6 (3·8) 5 (5·0) 9 (7·9)
Pyrexia 5 (5·1) 6 (3·8) 1 (1·0) 1 (0·9)
Upper respiratory tract infection 4 (4·0) 4 (2·6) 1 (1·0) 1 (0·9)
Bronchitis 3 (3·0) 4 (2·6) 4 (4·0) 5 (4·4)
Conjunctivitis 3 (3·0) 3 (1·9) 1 (1·0) 1 (0·9)
Cough 3 (3·0) 3 (1·9) 3 (3·0) 3 (2·6)
Otitis media 3 (3·0) 4 (2·6) 1 (1·0) 1 (0·9)
Pharyngitis 3 (3·0) 3 (1·9) 0 (0·0) 0 (0·0)
Vomiting 3 (3·0) 3 (1·9) 1 (1·0) 1 (0·9)
Application site erythema 2 (2·0) 2 (1·3) 1 (1·0) 1 (0·9)
Gastroenteritis 2 (2·0) 2 (1·3) 0 (0·0) 0 (0·0)
Herpes simplex infection 2 (2·0) 2 (1·3) 0 (0·0) 0 (0·0)
Rhinitis 2 (2·0) 2 (1·3) 4 (4·0) 4 (3·5)
  • ID, incidence density of an adverse event (AE) (which had a crude incidence rate of ≥ 2%) per 1000 patient-days = number of occurrences of that AE, divided by the total number of days during which patients were studied, multiplied by 1000.

The correct version of Table 1 is shown below:

We apologise for the error.

    The full text of this article hosted at iucr.org is unavailable due to technical difficulties.